Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB Ophthalmics Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for GKB Ophthalmics's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GKB vs ISRG, BDX, MDLN: Total Payout Ratio Comparison
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics (NSE:GKB) has a Total Payout Ratio of 0.00 as of Aug. 26, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on GKB Ophthalmics and its competitors.
Is GKB Ophthalmics' Total Payout Ratio too high?
GKB Ophthalmics' current Total Payout Ratio is 0.00. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' Total Payout Ratio compare to ISRG and BDX?
GKB Ophthalmics' Total Payout Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on GKB Ophthalmics and its competitors. GKB Ophthalmics's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.38, compared to a current price of ₹63.00 — trading 50.2% below its estimated fair value. The current Total Payout Ratio is 0.00. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current Total Payout Ratio is 0.00 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.2% below its estimated GF Value™ of ₹126.38.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
Total Payout Ratio: 0.00
GF Value™: ₹126.38 vs. price of ₹63.00 (50.2% below fair value)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
